Hospitalized incident cases of MRSA to reach 791,000 in 7MM in 2033

MRSA

Hospitalized incident cases of MRSA to reach 791,000 in 7MM in 2033

The burden of hospitalized incident cases of methicillin-resistant Staphylococcus aureus (MRSA) is forecast to increase at an annual growth rate (AGR) of 1.08% from around 714,000 cases in 2023 to 791,000 cases in 2033 in the seven major markets (7MM*), according to GlobalData, a leading data and analytics company.

GlobalData’s latest report, ‘Methicillin Resistant Staphylococcus aureus (MRSA): Epidemiology Forecast to 2033’, reveals that the increase in MRSA cases is partly attributed to poor infection control and a subsequent increase in antibiotic-resistant bacteria across the 7MM, combined with underlying demographic changes in the respective markets.

 

Initially, MRSA infections were typically acquired in a healthcare environment, however in more recent years community-acquired MRSA infections have predominated. According to GlobalData epidemiologists, there were 552,000 community-acquired hospitalized incident cases of MRSA in 2023, and 162,000 healthcare-acquired cases in the 7MM.

Anna Moody, MRES, Epidemiologist at GlobalData, comments: “Infection control in healthcare settings has vastly improved across the 7MM over the past decade; however, the appropriate adjustment of hygiene practices in community settings lacks consideration for the presence of antibiotic-resistant bacteria, like MRSA. This explains why the number of community-acquired hospitalized incident cases of MRSA is higher than healthcare-acquired cases.”

GlobalData epidemiologists expect that across the 7MM, the community-acquired cases of MRSA will increase to 612,000 by 2033, at an AGR of 1.09%, whilst the healthcare-acquired cases will increase to 179,000 by 2033, at an AGR of 1.05%.

Moody concludes: “As the incidence of antibiotic-resistant bacteria increases, there should be an improved focus on infection control, both in and out of healthcare settings, and practitioners should avoid inappropriate and over-use of antibiotics where possible.”

*7MM: The US, France, Germany, Italy, Spain, the UK, and Japan

Source: GlobalData